Quarterly Results

202602 Results Summary

Revenue

The revenue stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Operating Profit

Operating Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

PBDT

PBDT stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Profit Before Tax

Profit Before Tax stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.

Net Profit

Net Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This represents a per cent year-on-year *(YoY) decline for the same year.

  • YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.

Company News

More

Earnings

CategoryQ3 FY25-26Q3 FY24-25Change %FY24-25FY23-24Change %
Total Revenue8,753.408,381.204.4432,643.9028,011.1016.54
Expenses6,838.906,108.6011.9624,096.8020,078.0020.02
Other Income271.10154.4075.581,119.00909.0023.10
Operating Profit365.50236.1054.819,666.108,842.109.32
Depreciation521.00471.4010.521,703.701,470.0015.90
Interest94.4081.7015.54282.90171.1065.34
Profit Before Tax1,543.201,874.30-17.677,679.507,201.006.64
Tax353.60470.10-24.782,258.101,945.9016.04
Net Profit1,209.901,413.70-14.425,725.205,577.902.64
CategoryQ3 FY25-26Q2 FY25-26Change %
Total Revenue8,753.408,828.30-0.85
Expenses6,838.906,751.101.30
Other Income271.10330.20-17.90
Operating Profit365.50420.90-13.16
Depreciation521.00504.603.25
Interest94.4090.704.08
Profit Before Tax1,543.201,744.80-11.55
Tax353.60408.00-13.33
Net Profit1,209.901,347.10-10.18

Research Reports

ActionTarget Price (₹)BrokerDateReports
Data Not Found

Financial Reports

Data not available.

Stock Prices Compare with Peers

Company1 Day1 Week1 Month3 Months6 Month1 Year
Data Not Found

Corporate Information

Company News

Stocks to Watch today, Jan 7: Titan, Biocon, Godrej Con, Lodha, YES Bank

Stocks to Watch today, January 7, 2026: Godrej Consumer, Titan, Jubilant FoodWorks, YES Bank are among key stocks that will be in focus today

Updated On: 07 Jan 2026 | 7:55 AM IST

Dr Reddy's Laboratories launches hepatitis E vaccine Hevaxin in India

The company said Hevaxin is the only hepatitis E vaccine approved by the Drug Controller General of India (DCGI) and is indicated for active immunisation against HEV infection

Updated On: 06 Jan 2026 | 8:41 PM IST

Antique prefers domestic-focused pharma firms; resumes coverage on 4 stocks

Antique resumed coverage on Torrent Pharma with a 'buy' rating, Cipla and Dr Reddy's Lab with 'hold' ratings, and Concord Biotech with a 'buy' rating

Updated On: 29 Dec 2025 | 11:24 AM IST

Stocks to Watch today, Dec 15: Swiggy, BEL, Tata Elxsi, Aurobindo Pharma

Stocks to watch today, December 15, 2025: From Tata Elxsi to Aurobindo Pharma, here is a list of stocks to keep in focus

Updated On: 15 Dec 2025 | 7:48 AM IST

Larger HC Bench clears way for export of semaglutide generics by Dr Reddy's

Novo Nordisk's appeal was listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla

Updated On: 12 Dec 2025 | 7:50 PM IST

Dr Reddy's signs licensing pact with Immutep to develop, market cancer drug

According to the agreement, Immutep will receive from Dr Reddy's an upfront payment of $20 million (around AUD 30.2 million)

Updated On: 08 Dec 2025 | 5:45 PM IST

Dr Reddy's signs licensing pact to sell Australian Immutep's cancer drug

Over the last few years, Dr Reddy's has diversified its portfolio beyond generics to include cancer therapies as it battles pricing pressures in North America, its largest market

Updated On: 08 Dec 2025 | 2:49 PM IST

Rupee at record low, MPC caution drag Nifty; check strategy, stock picks

Sentiment was dampened by a weakening rupee, which hit a record low of 90.13 against the dollar, heightening concerns around import costs and triggering FII outflows

Updated On: 04 Dec 2025 | 7:30 AM IST

Nifty50 to hit 29,300 by end-2026? Nomura lists top 20 stock picks

Nomura expects Indian markets to trade in the range of 20-22x one-year forward earnings, assuming risk premia remain low.

Updated On: 02 Dec 2025 | 9:13 AM IST

Why did Dr Reddy's share rise over 2% in overall subdued market? Details

At 12:30 PM, Dr. Reddy's shares were trading 2.03 per cent higher at ₹1,249.65 per share. In comparison, BSE Sensex was trading flat with a positive bias at 84,943.47 levels.

Updated On: 25 Nov 2025 | 12:39 PM IST
More